Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy
Jessica Dahmus, Michelle Rosario, Kofi Clarke Gastroenterology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USACorrespondence: Kofi Clarke Tel +1 717-531-8741Fax +1 717-531-6770Email kclarke@pennstatehealth.psu.eduAbstract: Anti-tumor necrosis factor alpha (ATA) therapy plays a signifi...
Main Authors: | Dahmus J, Rosario M, Clarke K |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-09-01
|
Series: | Clinical and Experimental Gastroenterology |
Subjects: | |
Online Access: | https://www.dovepress.com/risk-of-lymphoma-associated-with-anti-tnf-therapy-in-patients-with-inf-peer-reviewed-article-CEG |
Similar Items
-
Hepatosplenic T-Cell Lymphoma: A Rare Complication of Monotherapy with Thiopurines in Crohn’s Disease
by: Joana Carvão, et al.
Published: (2018-11-01) -
Inflammatory Bowel Diseases: Focus on Therapy
by: Cristina Tocia, et al.
Published: (2018-02-01) -
Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease
by: Gian Paolo Caviglia, et al.
Published: (2021-07-01) -
Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease
by: Amir Klein, et al.
Published: (2010-04-01) -
Blastic morphology in a Hepatosplenic T-Cell lymphoma
by: avinash kumar singh, et al.
Published: (2014-08-01)